EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern

Arturo Casadevall, Daniele Focosi

Journal of Clinical Investigation · 2023

DOI: 10.1172/jci168603 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Arturo Casadevall und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 and manifest infection outcomes ranging from severe disease to persistent infection. Weakened immune systems mean greater viral loads and increased opportunities for viral evolution. Gupta, Konnova, et al. report the emergence of resistant SARS-CoV-2 variants in immunocompromised patients after monoclonal antibody (mAb) therapy. mAbs target only a single determinant in the viral Spike protein, which is a weakness of such therapy when treating a mutagenic and variable virus. Hence, the emergence of mAb resistance could have been anticipated, but its documentation is important because it has major public health implications, since such resistant variants have the potential to spread and escape vaccine immunity. For immunocompromised patients, these findings suggest the need for combination therapy with antiviral drugs and the use of polyclonal antibody preparations such as convalescent plasma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansAntibodies, MonoclonalPublic HealthCOVID-19 SerotherapyImmunocompromised HostAntibodies, ViralAntibodies, Neutralizing

Substanzen

Antibodies, MonoclonalAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Casadevall, A., & Focosi, D. (2023). SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. Journal of Clinical Investigation. https://doi.org/10.1172/jci168603

Vancouver

Casadevall A, Focosi D. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. Journal of Clinical Investigation. 2023. doi:10.1172/jci168603

BibTeX
@article{Casadevall2023,
  author = {Casadevall, Arturo and Focosi, Daniele},
  title = {SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1172/jci168603}
}
Kostenlos starten →